Clinical trial

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366

Study summary

ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention QCC374 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Matching Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-09-19

PhasePHASE2

Conditions

Pulmonary Arterial Hypertensionverified · MONDO: pulmonary arterial hypertension

Interventions

QCC374DRUG

Placebo MatchingDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

SeoulSouth Korea1 PittsburghPennsylvania, United States1 DresdenGermany1 HeidelbergGermany1 CambridgeCambridgeshire, United Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02927366 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.